From: Epigenetic transgenerational inheritance of somatic transcriptomes and epigenetic control regions
 | 11 male and female tissues | Sex and tissue | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
 |  | Male | Female | |||||||||||
 |  | 6 tissues | Heart | Kidney | Liver | Prostate | SV | Testis | 5 tissues | Heart | Kidney | Liver | Ovary | Uterus |
Pathway name | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
Number of genes in input list | 4059 | 3046 | 172 | 725 | 266 | 1112 | 274 | 552 | 1298 | 408 | 151 | 99 | 305 | 279 |
Total number of affected pathways | 230 | 224 | 79 | 151 | 141 | 191 | 90 | 99 | 191 | 108 | 79 | 29 | 80 | 138 |
Pathways in cancer | 45 | 32 | 3 | 7 | 6 | 13 | 1 | 2 | 17 | 6 | 3 | 1 | 3 | 4 |
Protein processing in endoplasmic reticulum | 39 | 38 | 3 | 4 | 1 | 22 | 5 | 4 | 3 | 1 | Â | Â | 1 | 1 |
HTLV-I infection | 39 | 31 | Â | 8 | 3 | 14 | 3 | 2 | 10 | 4 | 2 | Â | 1 | 3 |
RNA transport | 39 | 31 | 1 | 8 | Â | 17 | 3 | 6 | 11 | 4 | Â | 1 | 2 | 4 |
Transcriptional misregulation in cancers | 31 | 26 | 1 | 8 | 6 | 7 | 4 | 3 | 12 | 6 | 3 | 1 | Â | 3 |
Herpes simplex infection | 30 | 23 | 2 | 10 | 3 | 7 | 2 | 1 | 9 | 3 | 1 | Â | 2 | 3 |
Lysosome | 29 | 27 | 1 | 5 | 4 | 16 | 2 | 2 | 5 | 1 | Â | Â | 1 | 3 |
Ribosome | 29 | 27 | 2 | 5 | Â | 1 | Â | 20 | 4 | 1 | 1 | 2 | Â | Â |
Endocytosis | 29 | 26 | 1 | 4 | 8 | 11 | 1 | 3 | 5 | 2 | Â | Â | Â | 3 |
Phagosome | 28 | 27 | 1 | 6 | 6 | 12 | Â | 2 | 7 | Â | 3 | Â | Â | 4 |
MAPK signaling pathway | 28 | 21 | 1 | 7 | 3 | 7 | 1 | 2 | 8 | 3 | Â | Â | 1 | 4 |
Spliceosome | 27 | 17 | Â | 8 | 1 | 1 | 2 | 7 | 12 | 6 | 1 | Â | 1 | 5 |
Regulation of actin cytoskeleton | 26 | 24 | 1 | 6 | 6 | 9 | Â | 3 | 5 | 3 | Â | 1 | Â | 1 |
Alzheimer's disease | 26 | 22 | 2 | 4 | Â | 7 | Â | 10 | 5 | Â | Â | Â | 2 | 3 |
Huntington's disease | 26 | 22 | 1 | 6 | Â | 2 | Â | 14 | 5 | 1 | Â | 1 | 2 | 1 |
Purine metabolism | 26 | 22 | 1 | 6 | 2 | 4 | 2 | 6 | 7 | 2 | Â | Â | Â | 5 |
Focal adhesion | 26 | 21 | 2 | 2 | 7 | 8 | Â | 3 | 9 | 3 | Â | 2 | Â | 4 |
Chemokine signaling pathway | 24 | 23 | 3 | 4 | 6 | 9 | 1 | 1 | 4 | Â | Â | Â | 2 | 2 |
Pyrimidine metabolism | 24 | 20 | 1 | 6 | 1 | 6 | 1 | 5 | 6 | 1 | Â | 1 | 1 | 3 |
Tuberculosis | 24 | 20 | Â | 6 | 6 | 9 | 1 | Â | 9 | 1 | 1 | Â | Â | 7 |
Influenza A | 23 | 21 | 1 | 5 | 2 | 11 | 1 | 3 | 5 | 1 | 2 | Â | Â | 2 |
Oxidative phosphorylation | 23 | 20 | 1 | 4 | Â | 5 | Â | 11 | 5 | Â | 1 | Â | 1 | 3 |
Leukocyte transendothelial migration | 22 | 18 | 2 | 1 | 7 | 8 | Â | 1 | 6 | 4 | 1 | Â | Â | 1 |
Cytokine-cytokine receptor interaction | 21 | 19 | 1 | 6 | 7 | 6 | Â | Â | 4 | 3 | Â | Â | Â | 1 |
Osteoclast differentiation | 21 | 18 | 1 | 2 | 6 | 10 | 1 | Â | 5 | 1 | Â | Â | 1 | 3 |
Cell adhesion molecules | 20 | 14 | 2 | 3 | 4 | 6 | 1 | Â | 7 | 3 | 1 | Â | 1 | 2 |
Insulin signaling pathway | 19 | 13 | Â | 2 | 3 | 6 | 2 | Â | 6 | 2 | Â | Â | Â | 4 |
mRNA surveillance pathway | 19 | 13 | 1 | 4 | Â | 5 | 2 | 4 | 8 | 4 | Â | Â | 2 | 2 |